UNEVEN FRONTIERS

Summary from the TLDR newsletter

AI will make some parts of biopharma faster and cheaper, but other facets of the industry are restricted by the physical world. Recruiting patients, dosing them, and waiting for results will still take time. Drug discovery will accelerate, but clinical development will remain a bottleneck. The durable position is built around the bottleneck, not in the path of advancing discovery models.